1. Home
  2. DSM vs NGEN Comparison

DSM vs NGEN Comparison

Compare DSM & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BNY Mellon Strategic Municipal Bond Fund Inc.

DSM

BNY Mellon Strategic Municipal Bond Fund Inc.

HOLD

Current Price

$6.01

Market Cap

306.0M

Sector

Finance

ML Signal

HOLD

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$3.77

Market Cap

317.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
DSM
NGEN
Founded
1989
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
306.0M
317.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DSM
NGEN
Price
$6.01
$3.77
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
95.0K
99.6K
Earning Date
01-01-0001
04-02-2026
Dividend Yield
3.97%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.28
$3.51
52 Week High
$6.30
$5.93

Technical Indicators

Market Signals
Indicator
DSM
NGEN
Relative Strength Index (RSI) 44.72 42.43
Support Level $5.89 $3.69
Resistance Level $6.26 $4.10
Average True Range (ATR) 0.07 0.22
MACD -0.01 0.00
Stochastic Oscillator 56.67 49.15

Price Performance

Historical Comparison
DSM
NGEN

About DSM BNY Mellon Strategic Municipal Bond Fund Inc.

BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: